Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.
Tomas JelinekTereza PopkovaJuraj DurasJana MihalyovaMichal KascakKaterina BenkovaHana PlonkovaLucie CernaZdenek KoristekMichal SimicekRoman HajekPublished in: Hematological oncology (2020)